Acta Ophthalmologica · 2013 · 39 citations · 30 references
MedicineEndocrinologyOphthalmologyDiabetologyOcular DiseaseOcular PathologyDiabetes ManagementDiabetes MellitusDiabetic RetinopathyGlycemic ControlGlycemic MonitoringRetinal Vascular DiseaseDiabetic Retinopathy AssessmentDiabetic Retinopathy GradingNon-proliferative Diabetic RetinopathyNonproliferative Diabetic RetinopathyRetinopathy Severity Grading
Purpose: To determine whether glycemic control of patients with diabetic retinopathy (DR) due to type 2 diabetes was related to VEGF plasma levels. Methods: The prospective study included 30 patients with DR due to type 2 diabetes. Retinopathy was classified according to the international clinical DR disease severity scale. The concentrations of VEGF in the blood plasma were measured by ELISA. Glycosylated hemoglobin (HbA1c) was assessed all patients. Results were reported as DCCT/NGSP-HbA1c (%) values. Results: The median plasma level of VEGF was 34.5 (range 15–217) pg/ml. Median HbA1c was 7.5 (range 5.3–10.6). The highest individual plasma VEGF measurements were found in patients with severe non-proliferative DR. HbA1c levels revealed a significant correlation with plasma VEGF concentrations (r = 0.573, p = 0.001). Age (r = 0.097, p = 0.611), gender (r = −0.315, p = 0.09) and severity of DR (r = 0.256, p = 0.172) were with no significant relationship to the VEGF measurements. Conclusion: Poor glycemic control is positively correlated with increased levels of plasma VEGF in patients with type 2 diabetes. As normalization of HbA1c is one of the most effective ways to prevent progression of DR and VEGF has been to shown to be clearly implicated in the development of DR, it affirms the importance of glycemic control in patients with DR. The metabolic changes in diabetes lead to widespread cellular damage with diabetes-associated microvasculopathy as the pivotal mediator for nephropathy, neuropathy and retinopathy (De Vriese et al. 2000). Diabetic retinopathy (DR) is the most severe of the ocular complications of diabetes (Frank 2004). It ultimately affects 70–100% of all patients with diabetes and represents the leading cause of blindness in industrialized countries in patients aged 20–64 (Klein et al. 1984; Dwyer et al. 1985). Serum hemoglobin A1c (HbA1c) is the most widely used clinical parameter for the evaluation of glycemic control in patients with diabetes. Hereby the amount of glycated hemoglobin is measured quantitatively. HbA1c correlates well with average plasma glucose concentration and provides a moving average of blood glucose over the preceding three months (Barr et al. 2002). HbA1c concentration has an inverse relationship with the incidence of developing DR. The risk of retinopathy was lowest in those patients with HbA1c levels around 7–7.5% and HbA1c normalization is one of the most effective systemic measures to prevent progression (DCCTR 1993; Rohlfing et al. 2002). The earliest clinical signs of DR are microaneurysms, small outpouchings from retinal capillaries, and dot intraretinal hemorrhages. With disease progression the most common manifestation of ocular disease activity in patients with type 2 diabetes is the presence of diabetic macular edema (DME), whereas in patients with type 1 diabetes development of retinal neovascularization is mostly seen first. These fragile proliferations pose an ominous risk for visual loss due to vitreous hemorrhage and its sequel complications (Aiello et al. 1994; Frank 2004). Intravitreal anti-VEGF injections have been shown to be beneficial in the treatment of DME as well as of neovascular DR and it can be assumed that VEGF acts as a key factor in the development of ocular complications in type 1 and 2 diabetes (Elman et al. 2011; Filho et al. 2011). Vascular endothelial growth factor (VEGF) is an endothelial cell selective cytokine that acts as a mitogen and induces microvascular permeability (Ferrara et al. 1992). Of the five isoforms VEGF 165 is the predominant subtype. It is a 45-kDa homodimeric glycoprotein detectable both free in the cytoplasm and bound through a heparin-binding domain to the cell surface and extracellular matrix and is the isoform principally responsible for mediating the pathological effects of VEGF in ocular neovascular diseases (Ishida et al. 2003; Usui et al. 2004). The vitreous levels of VEGF are positively correlated with the development of neovascularization in different ocular disease entities including DR (Adamis et al. 1994; Aiello et al. 1994). Furthermore significantly raised VEGF plasma levels have been observed in patients with DR compared to non-diabetic controls (Lip et al. 2004). These findings suggest that plasma VEGF levels may be used as a potential indicator for neovascularization in diabetic patients and that the underlying pathomechanism implies systemic as well as local ocular angioneogenetic pathways (Lip et al. 2004; Cavusoglu et al. 2007a,b). The purpose of this study was to determine whether glycemic control of patients with DR due to type 2 diabetes was related to VEGF plasma levels. The study was planned as a prospective study at Department of Ophthalmology, Medical University Innsbruck. Informed consent was obtained from all participants in accordance with the tenets of the Declaration of Helsinki, and the study was approved by the Ethics Review Board of the Medical University Innsbruck. Patients with type 2 diabetes and DR were recruited from the diabetic outpatient clinic at the department of ophthalmology. All patients did not receive intravitreal injections for at least three months prior to inclusion. Patients with anti-inflammatory treatment like steroids were excluded. Eyes that had undergone vitrectomy were excluded. Subjects with chorioretinal abnormalities, uncontrolled hypertension and other vasoproliferative disorders were excluded. The diagnosis of DR was performed by fundus examination after pupil dilation with tropicamide and phenylephrine 2.5% using slit-lamp biomicroscopy and optical coherence tomography in selected cases (Heidelberg Spectralis® OCT, Heidelberg Engineering, Heidelberg, Germany). Retinopathy was classified according to the international clinical DR disease severity scale. This classification consists of five stages. It includes three stages of low risk, a fourth stage of severe non-proliferative retinopathy, and a fifth stage of proliferative retinopathy (Wilkinson et al. 2003). The study group consisted of 30 patients (21 male, 9 female) with a mean age of 67.3 ± 7.7 years (range: 56–88). Blood samples were drawn from all participants by venous puncture with minimal stasis. Glycosylated hemoglobin (HbA1c) was assessed in all patients. Results were reported as DCCT/NGSP-HbA1c (%) values (Rohlfing et al. 2002). For the VEGF assay blood samples were collected in tubes containing EDTA. Centrifugation was done at 3000 rpm for 20 min within an hour after sampling. Plasma was stored at −20°C until the assay, which was done within 4 weeks after sampling. VEGF plasma levels were determined by ELISA (#DVE00; Quantikine VEGF ELISA Kit, R&D Systems Europe, Abingdon, OX14 3NB, UK) as described by the manufacturer. 100 μl of assay diluents RD1W was added to each well of 96 well polystyrene micro plates then 100 μl of standard or samples (EDTA-plasma) was added to each well, mixed by gently tapping the plate frame for 1 min and incubated for 2 hr at room temperature. Afterwards, washing with wash buffer (400 μl) was performed for three times followed by addition of 200 μl of human VEGF conjugate to each well, incubation for 2 hr at room temperature and washing again with wash buffer for three times. Subsequently, 200 μl of substrate solution was added to each well, incubated for 25 min at room temperature and finally, 25 μl of stop solution was added to each well and the concentration was determined by an ELISA reader at 450 nm. A p value of less than 0.05 was considered to indicate statistical significance. Spearman’s rank correlation analyses were used to determine the correlation coefficients. Perfect concordance results in a correlation coefficient value of 1.0, and a coefficient value of 0.0 means that there is no concordance between operators. Differences between the groups were analyzed with the Mann–Whitney U test, 2 tailed. Analyses within one group were calculated by use of the Friedman test and the Wilcoxon signed rank test. For measurements that did not follow a Gaussian distribution according to the method of Shapiro-Wilk median and range values were calculated. The same applied to subgroup analyses with smaller sample sizes. Data were analyzed using SPSS statistical software (version 19.0, SPSS Inc., Chicago, IL, USA). The median plasma level of VEGF was 34.5 (range 15–217). Median HbA1c was 7.5 (range 5.3–10.6). According to the five-stage disease severity classification for DR 11 patients were classified into level 2 (36.7%) with microaneurysms only and 6 (20.0%) into level 3 (more than just microaneurysms but less than severe non-proliferative DR). The remaining two groups are those that carry the highest risk for visual deterioration with seven patients (23.3%) in stage 4 (severe non-proliferative DR) and 6 (20.0%) with proliferative DR. The highest individual plasma VEGF measurements were found in patients with severe non-proliferative DR (Table 1). No significant differences in mean HbA1c levels (p = 0.950) and plasma VEGF levels (p = 0.335) between patients with the first three stages of low risk DR and the other two groups exhibiting severe or proliferative retinopathy were shown. HbA1c levels revealed a significant correlation with plasma VEGF concentrations (r: 0.573, p = 0.001) (Fig. 1). Age (r = 0.097, p = 0.611), gender (r = −0.315, p = 0.09) and severity of DR (r = 0.256, p = 0.172) were with no significant relationship to the VEGF measurements. Scatter plot matrix of correlation between plasma VEGF levels and HbA1c (r = 0.573; p = 0.001; Spearman’s rank correlation coefficient). Intensive metabolic control of diabetic patients with the goal of maintaining their blood glucose level and glycosylated hemoglobin value as close as safely possible to the normal range delays the onset and slows progression of retinopathy (1993). In the literature significantly increased systemic plasma VEGF levels in diabetic patients compared to healthy controls have been detected (Meleth et al. 2005; Cavusoglu et al. 2007a; Petrovic et al. 2008; Ozturk et al. 2009). One pathophysiologic explanation for this relationship is that high blood glucose concentrations and subsequent formation of advanced glycation end products (AGE) have been shown to increase of VEGF gene transcription and mRNA production. Hence the accumulation of AGEs within tissue including the retina is suspected to upregulate VEGF production and therefore initiating and fostering the neovascularization process (Treins et al. 2001; Tamarat et al. 2003). Our data show a strong positive correlation between HbA1c and VEGF plasma levels. This highlights the role of VEGF in the development of diabetic complications including DR as in our patient cohort. This significant association is in line with other data that demonstrated higher VEGF concentrations in patients with type 2 diabetes hospitalized for poor glycemic control compared to healthy subjects (Kakizawa et al. 2004). VEGF acts as an endothelial cell specific cytokine that directly increases vascular permeability and it plays a pivotal in role in the development of microvascular complications (Ferrara et al. 1992; Carmeliet et al. 1996; Cavusoglu et al. 2007a). These properties contribute to understanding the pathophysiology and the effectiveness of intravitreal anti-VEGF therapy in diabetic maculopathy (Elman et al. 2011). The protective effect of good metabolic control of patients with DR patients reflected by low HbA1c concentrations may therefore in part be mediated by normalization of systemic VEGF levels. In accordance with that other studies documented that the increased VEGF production is reversed by the reduction of hyperglycemia (Kakizawa et al. 2004). Plasma VEGF levels may reflect the current risk for development of microvascular anomalies mediated by VEGF overproduction as well as the systemic disease activity level itself. Regarding the grading of disease activity of DR we could not demonstrate a clear trend towards lower VEGF plasma levels for those with less active DR. In the literature there are conflicting results regarding an association. In most publications VEGF serum levels were measured (Meleth et al. 2005; Cavusoglu et al. 2007a; Petrovic et al. 2008; Ozturk et al. 2009). Serum contains high levels of VEGF due to release by platelet activation during clotting (Verheul et al. 1997; Banks et al. 1998). Thrombocytes are the major source for vascular endothelial growth factor in peripheral blood (Gunsilius et al. 2000). Therefore VEGF levels in serum, which correlate closely with blood platelet count and platelet activation, do not reflect the actual circulating concentration of VEGF in vivo (Salgado et al. 1999; Niers et al. 2011). In summary the value of VEGF serum testing in diabetic patients remains in question and plasma VEGF analyses should be preferred. Considering those studies measuring VEGF plasma levels, investigators found markedly elevated VEGF levels in patients with DR compared to controls. No clear trend towards a correlation of systemic VEGF and the grading of DR could be demonstrated (Hovind et al. 2000; Chaturvedi et al. 2001). This is somewhat inconclusive as the study by Lip et al., in which proliferative ocular disease activity was directly modified by panretinal laser photocoagulation, showed a significant fall of systemic VEGF levels four months after successful treatment (Lip et al. 2000). There may be several reasons why systemic VEGF levels do not seem to correlate with ocular disease activity of DR. First, the currently available study data of plasma VEGF measurements have one weakness in common. The sample sizes in the subgroups categorized by the level of DR are relatively small and therefore may be responsible for apparent lack of association (Chaturvedi et al. 2001). Prospective studies with longer follow-up and larger sample sizes are needed to demonstrate a possible predictive power of plasma VEGF for the severity of DR. Second, other factors might influence disease progression of DR; there is an increasing scientific evidence for a pathogenic role of inflammation in proliferative DR which might influence disease progression. In line with this a number of proinflammatory cytokines have been shown to be consistently elevated in the vitreous of patients with advanced stages of DR (Adamis & Berman 2008; Schoenberger et al. 2012; Zhou et al. 2012). Finally, even though all patients with vasoproliferative disorders other than diabetes were not included in our study, it cannot be ruled out that systemic VEGF levels may have been affected by different systemic conditions. Moreover, after several years of type 2 diabetes nearly all organ systems are affected and therefore an exclusive correlation with eye disease activity seems nearly impossible. In summary the present study shows that poor glycemic control is significantly positively correlated with increased levels of plasma VEGF in patients with type 2 diabetes. As normalization of HbA1c is one of the most effective ways to prevent progression of DR and VEGF has been to shown to be clearly implicated in the development of DR, it affirms the importance of glycemic control in patients with DR (Frank 2004).
30
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Peter Carmeliet, Valérie Ferreira, Georg Breier et al. · Nature · 1996 · 4.1K citations
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Ronald Klein · Archives of Ophthalmology · 1984 · 1.9K citations